Stock Scorecard

Stock Summary for Bristol-Myers Squibb Company (BMY) - $47.18 as of 8/29/2025 8:19:33 PM EST

Total Score

11 out of 30

Safety Score

63 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for BMY

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BMY

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BMY

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for BMY

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for BMY (63 out of 100)

Stock Price Rating (Max of 10) 8
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 4
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 8
Operating Margin (Max of 10) 6
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 8
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for BMY

UPDATE - Questex's Fierce Pharma Week Announces Star-Studded Lineup with Jamie-Lynn Sigler, James Van Der Beek, Selma Blair, Kelly Killoren Bensimon and John Duffield to Provide Powerful Stories of Resilience and Healing 8/28/2025 5:30:00 PM
Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19 8/27/2025 4:50:00 PM
I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee - I-MAB ( NASDAQ:IMAB ) 8/25/2025 11:00:00 AM
HUTCHMED Announces Appointment of Acting Chief Executive Officer 8/25/2025 12:20:00 AM
HUTCHMED Announces Appointment of Acting Chief Executive Officer - HUTCHMED ( China ) ( NASDAQ:HCM ) 8/25/2025 12:20:00 AM
ServiceNow, Live Nation Entertainment And A Health Care Stock: CNBC's 'Final Trades' - Live Nation Entertainment ( NYSE:LYV ) , Bristol-Myers Squibb ( NYSE:BMY ) 8/22/2025 11:41:00 AM
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Medtronic ( NYSE:MDT ) , Bristol-Myers Squibb ( NYSE:BMY ) 8/19/2025 5:32:00 PM
Will AI's Diversification Beyond Oil & Gas Fuel Its Next Growth Phase? 8/19/2025 1:06:00 PM
How Do Investors Really Feel About Bristol-Myers Squibb? - Bristol-Myers Squibb ( NYSE:BMY ) 8/19/2025 1:00:00 PM
Investors Heavily Search Bristol Myers Squibb Company ( BMY ) : Here is What You Need to Know 8/19/2025 1:00:00 PM

Financial Details for BMY

Company Overview
Ticker BMY
Company Name Bristol-Myers Squibb Company
Country USA
Description Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 6/30/2025
Next Earnings Date 10/31/2025

Stock Price History
Last Day Price 47.18
Price 4 Years Ago 53.67
Last Day Price Updated 8/29/2025 8:19:33 PM EST
Last Day Volume 10,656,943
Average Daily Volume 11,739,770
52-Week High 61.84
52-Week Low 42.96
Last Price to 52 Week Low 9.82%

Valuation Measures
Trailing PE 18.83
Industry PE 40.47
Sector PE 60.89
5-Year Average PE 16.73
Free Cash Flow Ratio 7.62
Industry Free Cash Flow Ratio 15.46
Sector Free Cash Flow Ratio 30.76
Current Ratio Most Recent Quarter 1.21
Total Cash Per Share 6.19
Book Value Per Share Most Recent Quarter 8.57
Price to Book Ratio 5.56
Industry Price to Book Ratio 28.68
Sector Price to Book Ratio 26.74
Price to Sales Ratio Twelve Trailing Months 2.00
Industry Price to Sales Ratio Twelve Trailing Months 25.19
Sector Price to Sales Ratio Twelve Trailing Months 13.32
Analyst Buy Ratings 4
Analyst Strong Buy Ratings 3

Share Statistics
Total Shares Outstanding 2,035,440,000
Market Capitalization 96,032,059,200
Institutional Ownership 82.88%

Dividends
Ex-Dividend Date 7/3/2025
Previous Dividend Amount 0.6200
Current Dividend Amount 0.6200
Total Years Dividend Increasing 3
Trailing Annual Dividend Rate 2.46
Trailing Annual Dividend Yield 5.16%
Forward Annual Dividend Rate 2.48
Forward Annual Dividend Yield 5.20%
5-Year Dividend Payments Count 20
3-Year Average Dividend Yield 4.40%
5-Year Average Dividend Yield 4.25%
1-Year Dividend Growth Rate Percentage 3.33%
3-Year Dividend Growth Rate Percentage 1.65%
5-Year Dividend Growth Rate Percentage 2.01%
All-Time Dividend Growth Rate Percentage 7.25%
Dividend Payout Ratio 98.80%

Income Statement
Quarterly Earnings Growth YOY -22.80%
Annual Earnings Growth -211.50%
Reported EPS 12 Trailing Months 2.49
Reported EPS Past Year 3.26
Reported EPS Prior Year 1.14
Net Income Twelve Trailing Months 5,049,000,000
Net Income Past Year -8,948,000,000
Net Income Prior Year 8,025,000,000
Quarterly Revenue Growth YOY 0.60%
5-Year Revenue Growth 13.06%
Operating Margin Twelve Trailing Months 33.70%

Balance Sheet
Total Cash Most Recent Quarter 12,599,000,000
Total Cash Past Year 10,346,000,000
Total Cash Prior Year 11,464,000,000
Net Cash Position Most Recent Quarter -31,871,000,000
Net Cash Position Past Year -37,257,000,000
Long Term Debt Past Year 47,603,000,000
Long Term Debt Prior Year 36,653,000,000
Total Debt Most Recent Quarter 44,470,000,000
Equity to Debt Ratio Past Year 0.26
Equity to Debt Ratio Most Recent Quarter 0.28
Total Stockholder Equity Past Year 16,335,000,000
Total Stockholder Equity Prior Year 29,430,000,000
Total Stockholder Equity Most Recent Quarter 17,435,000,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months 14,578,000,000
Free Cash Flow Per Share Twelve Trailing Months 7.16
Free Cash Flow Past Year 13,942,000,000
Free Cash Flow Prior Year 12,651,000,000

Options
Put/Call Ratio 0.83
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD 0.29
MACD Signal 0.25
20-Day Bollinger Lower Band 44.55
20-Day Bollinger Middle Band 47.18
20-Day Bollinger Upper Band 49.81
Beta 0.37
RSI 52.54
50-Day SMA 51.78
150-Day SMA 53.03
200-Day SMA 54.95

System
Modified 8/29/2025 7:07:07 PM EST